Medical Oncology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Oncologist. 2024 Jan 5;29(1):e152-e163. doi: 10.1093/oncolo/oyad211.
This study's purpose was to assess symptom cluster (SC) stability during disease progression and determine their strength of association with survival in patients with advanced cancer . Consecutively eligible patients with advanced cancer not receiving cancer-specific treatment and referred to a Tertiary Palliative Care Clinic were enrolled in a prospective cohort study. At first consultation (D0) and in subsequent consultations at day 15 (D15) and day 30 (D30), patients rated 9 symptoms through the Edmonton Symptom Assessment System scale (0-10) and 10 others using a Likert scale (1-5). Principal components factor analysis with varimax rotation was used to determine SCs at each consultation. Of 318 patients with advanced cancer, 301 met eligibility criteria with a median age of 69 years (range 37-94). Three SCs were identified: neuro-psycho-metabolic (NPM), gastrointestinal, and sleep impairment, with some variations in their constitution over time. Exploratory factor analysis accounted for 40% of variance of observed variables in all SCs. Shorter median survival was observed continuously for NPM cluster (D0 23 vs. 58 days, P < .001; D15 41 vs. 104 days, P=.004; D30 46 vs. 114 days, P = .002), although the presence of 2 or more SCs on D0 and D15 also had prognostic significance (D0: 21 vs. 45 days, P = .005; D30: 50 vs. 96 days, P = .040). In a multivariable model, NPM cluster (D0 hazard ratio estimate: HR 1.64; 95%CI, 1.17-2.31; P = .005; D15 HR: 2.51; 95%CI, 1.25-5.05; P = .009; D30 HR: 3.9; 95%CI, 1.54-9.86; P = .004) and hospitalization (D0 HR: 2.27; 95%CI, 1.47-3.51; P < .001; D15 HR: 2.43; 95%CI, 1.18-5.01; P = .016; D30 HR: 3.41; 95%CI, 1.35-8.62; P = .009) were independently and significantly associated with worse survival. Three clinically relevant SCs were identified, and their constitution had small variations, maintaining a stable set of nuclear symptoms through disease progression. Presence of the NPM cluster and hospitalization maintained their prognostic value over time.
这项研究的目的是评估疾病进展过程中症状群(SC)的稳定性,并确定它们与晚期癌症患者生存的关联强度。连续符合条件的未接受癌症特异性治疗且被转诊至三级姑息治疗诊所的晚期癌症患者被纳入前瞻性队列研究。在首次就诊(D0)以及随后的第 15 天(D15)和第 30 天(D30)就诊时,患者通过埃德蒙顿症状评估系统量表(0-10)对 9 种症状进行评分,通过李克特量表(1-5)对其他 10 种症状进行评分。采用最大方差旋转的主成分因子分析来确定每个就诊时的 SC。在 318 名晚期癌症患者中,有 301 名符合入选标准,中位年龄为 69 岁(范围 37-94 岁)。确定了三个 SC:神经心理代谢(NPM)、胃肠道和睡眠障碍,其构成随时间有一些变化。探索性因子分析在所有 SC 中解释了观察变量方差的 40%。尽管 D0 和 D15 存在 2 个或更多 SC 也具有预后意义(D0:21 天 vs. 45 天,P<.001;D30:50 天 vs. 96 天,P=.040),但 NPM 簇的中位生存期持续缩短(D0 23 天 vs. 58 天,P<.001;D15 41 天 vs. 104 天,P=.004;D30 46 天 vs. 114 天,P=.002)。在多变量模型中,NPM 簇(D0 危险比估计值:HR 1.64;95%CI,1.17-2.31;P=.005;D15 HR:2.51;95%CI,1.25-5.05;P=.009;D30 HR:3.9;95%CI,1.54-9.86;P=.004)和住院(D0 HR:2.27;95%CI,1.47-3.51;P<.001;D15 HR:2.43;95%CI,1.18-5.01;P=.016;D30 HR:3.41;95%CI,1.35-8.62;P=.009)与较差的生存独立且显著相关。确定了三个具有临床意义的 SC,它们的构成有微小变化,在疾病进展过程中保持稳定的核心症状集。NPM 簇的存在和住院治疗保持了它们随时间的预后价值。